TY - JOUR
T1 - Combined strategies for tumor immunotherapy with nanoparticles
AU - Savitsky, K.
AU - Yu, X.
N1 - Publisher Copyright:
© 2019, Federación de Sociedades Españolas de Oncología (FESEO).
PY - 2019/11/1
Y1 - 2019/11/1
N2 - A brief review of tumor immunotherapies shows significant advancements in academic research and preclinical studies. Analysis of different immune cell pathways, including macrophage activation, natural killer cells, and dendritic cell presentation show promising clinical results when targeted with different nanoparticle polymer and gold materials. Following a brief discussion on immuno-oncology successes, detailed results are discussed in macrophage activation, dendritic cell presentation, and lysis of tumor cells with natural killer cells. Common targets include tumor-associated macrophages and induction of the proinflammatory phenotype, dual targeting of cell and humoral immunity with dendritic cells, and creating chimeric antigen receptors on natural killer cells. An analysis of the results shows a variety of nanoparticle synthesis methods are required depending on drug type and tissue type affected by tumors. Future research is discussed in conjunction with a brief analysis of completed clinical trial data on cancer therapies using nanoparticles to date. Although paclitaxel-loaded albumin nanoparticles are most frequently studied, academic research shows there may be additional mechanisms of action to elicit anti-tumor activity.
AB - A brief review of tumor immunotherapies shows significant advancements in academic research and preclinical studies. Analysis of different immune cell pathways, including macrophage activation, natural killer cells, and dendritic cell presentation show promising clinical results when targeted with different nanoparticle polymer and gold materials. Following a brief discussion on immuno-oncology successes, detailed results are discussed in macrophage activation, dendritic cell presentation, and lysis of tumor cells with natural killer cells. Common targets include tumor-associated macrophages and induction of the proinflammatory phenotype, dual targeting of cell and humoral immunity with dendritic cells, and creating chimeric antigen receptors on natural killer cells. An analysis of the results shows a variety of nanoparticle synthesis methods are required depending on drug type and tissue type affected by tumors. Future research is discussed in conjunction with a brief analysis of completed clinical trial data on cancer therapies using nanoparticles to date. Although paclitaxel-loaded albumin nanoparticles are most frequently studied, academic research shows there may be additional mechanisms of action to elicit anti-tumor activity.
KW - Cancer immunotherapy
KW - Combination therapy
KW - Dendritic cell
KW - Immune checkpoint inhibitors
KW - Immunotherapy
KW - Nanoparticles
KW - Natural killer cell
KW - Neoplasms
KW - Tumor-associated macrophages
UR - http://www.scopus.com/inward/record.url?scp=85065426768&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065426768&partnerID=8YFLogxK
U2 - 10.1007/s12094-019-02081-3
DO - 10.1007/s12094-019-02081-3
M3 - Review article
C2 - 31055713
AN - SCOPUS:85065426768
SN - 1699-048X
VL - 21
SP - 1441
EP - 1449
JO - Clinical and Translational Oncology
JF - Clinical and Translational Oncology
IS - 11
ER -